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Objective. To identify disabilities caused by Buruli Ulcer Disease (BUD) when it aﬀects the Head and Neck Region (HNR) of
patients in endemic areas and suggest possible ways to overcome the complications involved. Methods. Data for the study was
collected from six diﬀerent hospitals in the central part of Ghana from 2004–2009. Diagnosis of BUD was based on clinical
ﬁndingsandconﬁrmedbypositiveresultofZiehl-NeelsonTestforAcidFastBacilli,PolymeraseChainReaction,orHistopathology.
Treatment of BUD involved a combinationof surgical interventions andantimycobacterial chemotherapy for 8 weeks. Results.T he
ageofthe 38 patients rangedfrom 0–56 years (meanage of14.3 years), with malesoutnumbering females.Most (55.3%,N = 21)
of the patients reported to the facilities with developed BUD deformities. Patients who lost their eyeball (N = 5) recorded the
highest in terms of functional disability. A mean total hospital stay of 52 days and follow-up period of 2.3 years were recorded for
the study. Conclusion. Visual impairment was the commonest form of disability recorded in the HNR. Management diﬃculties
and BUD disabilities could be avoided by early detection of the disease and training of health professionals at district levels.
1.Introduction
Buruliulcer(BU)isa severe disabling and disﬁguring disease
caused by Mycobacterium ulcerans (MU). Even though cases
arereportedinallagegroups,itaﬀectsprimarilychildrenless
than 15 years of age [1, 2]. Oluwasanmi et al. [3]a n dv a nd e r
Werf et al. [2] did not ﬁnd any sex diﬀerence in their studies,
but Barker reported prevalence to be higher among women
than men and among boys than girls. One characteristic of
the disease is its apparent association with aquatic habitat,
especially in many tropical and subtropical countries [3–6].
In early or preulcerative lesions, MU produces a lipid toxin,
mycolactone, which is responsible for necrosis of the dermis,
panniculus, and fascia, culminating in extensive ulcers [7].
Preulcerative lesions and small ulcers may be surgically
excised and closed. However, antimicrobial drug therapy is
often eﬀective for treatment of early lesions [8]. Large ulcers
generally require excision followed by skin grafting [9]i n
combination with BU chemotherapy [10].
In Ghana, BU is currently the second mycobacterial
infection after tuberculosis [11]. According to the Ghana
National Buruli Ulcer Control Programme, January—
December2009Report, 19 cases ofBU in the Head and Neck
Region (HNR) had been conﬁrmed in various regions of
the country, with Ashanti Region (in Central Ghana) alone
recording 52.6% of it [12]. BU may aﬀect all parts of the
body but most frequently the lower extremities. The disease
starts as a painless nodule or papule in the skin. If this is not
excised, necrosis of the skin and subcutaneous tissue may
result [13–15]. Sometimes it may cause tendinous or bone
exposure; when it involves a joint, contracture may result.
MU disease in the HNR, especially the face, may lead to
serious sequelae such as ulcerative destruction of the eyelids,
loss of the nose, or deformity of the face [16, 17]. Agbenorku
in 2005 reported BU in the HNR in his study conducted in
Ghana [17]. Similarly, Kouame et al. in Cote D’Ivoire [18]
and Phanzu et al. in Angola [19] had also reported BU in the
HNR.
M. ulcerans disease of the scalp may also lead to
permanent alopecia. After treatment of the ulcer, complex
reconstructive procedures may be required to restore a more
or less desired hairstyle. The objective of this retrospective2 Plastic Surgery International
study was to identify disabilities caused by Buruli Ulcer
Disease (BUD), when it aﬀects the HNR of patients in
endemic areas and suggests possible ways to overcome the
complications involved.
2.PatientsandMethods
2.1. Data Acquisition. Data for the study was retrieved
from six diﬀerent hospitals, which are: Komfo Anokye
Teaching Hospital, Kumasi; Global Evangelical Mission Hos-
pital, Apromase; SDA Hospital, Asamang; Bekwai District
Hospital, Bekwai; Nyinahin Government Hospital, Nyinahin
and Nkawie District Hospital, Nkawie all in the middle belt
of Ghana, from 2004–2009. The sources of information were
the operation registers and the case notes of the patients.
Information obtained included age, sex distribution, clinical
presentation (preulcerative and ulcer), location of BUD,
deformities presented, and surgical and antibiotic therapy.
Preulcerative lesions include plaque, papule and nonulcer-
ative edematous forms. Ethical clearance for the study was
obtainedfromtheAshanti RegionalHealthDirectorate.Data
obtained was recorded and displayed in tables and graphs by
using SPSS version 16.0 (SPSS, Inc., Chicago, Ill, USA).
2.2. Clinical and Laboratory Diagnosis. Diagnosis of BU was
based on clinical ﬁndings such as chronicity of the wound,
typical undermined edges with central necrotic tissues,
and failure to respond to traditional wound management
procedures and antibiotic therapy. The ﬁndings were then
conﬁrmed by any two of the following laboratory diagnosis:
Ziehl-Neelson Test for Acid Fast Bacilli, Polymerase Chain
Reaction, and Histopathology.
2.3. Patients Management
2.3.1. Patients Admitted with Deformities. The patients had
surgical excisions of the chronic ulcers. Some of them,
because of the location of the ulcers (immediately adjacent
to the eye) could not have complete excision. They were
dressed over long periods with normal saline or 2% acetic
acid lotions. Because of the diﬃculty in achieving good
hemostasis, some of the excised ulcers were grafted secon-
darily after 24–72 hours. Ulceration that extended to the
eyelid and base of the nose were treated by four surgical exci-
sions, daily wound dressings, and skin grafts. Patients with
eyelid destruction had them reconstructed with an Indian
forehead ﬂap. Surgery was combined with antimycobacterial
chemotherapy (Rifampin and Streptomycin) for 8 weeks.
The treatment necessitates long hospitalization and is quite
expensive with less complications. The patients came for
followup monthly for three visits and then quarterly.
2.3.2.PatientswithoutDeformities. PatientswithBUthathad
good healthy edges with hypertrophic granulation had only
sharp debridement done. After meticulous hemostasis, the
wounds were covered with split-thickness skin grafts or local
transposition ﬂaps. The grafts were dressed with Vaseline
gauzeandtie-overdressings. Therecipientsitedressings were
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Figure 1: Age distribution of patients with BU in the HNR.
Figure 2: Patient with BUD on the eye region.
changed on the 4th or 5th postoperative day while the donor
sites (normally the thigh) were changed on the 14th day
after operative day. Similarly, surgery was combined with
Rifampin and Streptomycin treatment for 8 weeks. Most of
the grafts healed within two weeks and the patients were
discharged home.
3.Results
3.1. Demographic Characteristics of Patients. During the
study period, 38 patients with BU in the HNR were recorded
of which males’ outnumbered females of a ratio 3:2,
respectively. The age of patients ranged from 0–56 years
(mean age of 14.3 years), while majority (65.8%, N = 25)
of them were pupils (5–15 years), as shown in Figure 1.I n
addition, total hospital stay of patients ranged from 15–60
days (Mean duration of 52 days), while follow-up period
of the study ranged from 1–5 years (Mean duration of 2.3
years), of which majority (85%, N = 32) of the patients were
captured in the period. Again, most (55.3%, N = 21) of
the patients reported to the facilities with already developed
BUD deformities. More than half (60.5%, N = 23)) of the
patients developed facial scars after treatment.
3.2. Clinical Stages and Location. The most prevalent clinical
presentations ofthe disease in theHNRwere severeand mild
ulcers(76.3%, N = 29), while no nodular stage was recorded.Plastic Surgery International 3
Table 1: Clinical presentation and location of BU in the HNR.
Location Clinical presentation
Severe ulcer Mild ulcer Plaque Edematous forms Total (%)
Eye & forehead region 8 12 2 1 23 (59.6)
Cheek & nose region 2 0 0 2 4 (10.5)
Neck region 3 4 3 1 11 (29.9)
Total (%) 13 (34.2) 16 (42.1) 5 (13.2) 4 (10.5)
Figure 3: Patient with destroyed Eyeball due to BUD.
Figure 4: Patient with BUD aﬀecting the Eyelid.
Figure 5: Patient with BUD located on the cheek.
Figure 6:FacialScardeveloped after InitialSurgery ofa BUPatient.
In terms of location BUD on the HNR, three divisions (Eye
& Forehead; Cheek & Nose; Neck regions) were made, with,
the Eye and Forehead region, recording the highest (59.6%,
N = 23) (Table 1). Representative results of the locations are
shown in Figures 2, 3, 4, 5, 6.
3.3. BUD Deformities Presented by Patients. Ah i g hn u m b e r
(55.3%, N = 21) of the BU patients reported to the facilities
with already developed deformities. These sequelae includes
stiﬀness of the neck (N = 4 ) ,l o s so fp a r to ft h ee a r( N = 2),
loss of part the nose (N = 1), loss of part of the lower lips (N
= 2), loss of the eyeball (N = 5), loss of the eyelid (N = 4),
and baldness (N = 3) at the frontal part of the head.
4.Discussion
Infection due to Mycobacterium ulcerans or BU usually
occurs on the limbs or trunk. Involvement of the head
and neck region is less frequent but can lead to serious
sequelae. Novelties in the study includes BU treatment
regime involving the HNR of patients with or without
sequelae and data to support the fact that BUD is also
detrimental not only the limbs of the body, but also the
HNR. According to the World Health Organisation (WHO),
a functional concept of disability, deﬁnes a disability as any
long-term limitation in activity resulting from a condition or
health problem.
The study conﬁrms ﬁndings elsewhere that the disease
aﬀects children more than adults [1, 2]. Marston et al. found
the highest rate of infection among children 10–14 years
of age in a disease-endemic area in the Daloa Region of
Cˆ ote d’Ivoire [20]. This observation has been misinterpreted4 Plastic Surgery International
to mean that the disease aﬀects only children. This study
demonstrates that all age groups can be aﬀected; however,
children (6–10 years) recorded the highest infection rate in
terms of BUD in the HNR. The results of our study again
reveal that males outnumbered females and this had been
conﬁrmed by many BU studies [11, 17, 18].
In the “BU on the face” case report of Phanzu et al.,
series of surgical interventions were performed and antimy-
cobacterial chemotherapy (Rifampin and Ciproﬂoxacin) was
given for sixty days [19]. Similar surgical interventions
were performed in this study especially, for patients who
delayed in seeking medical treatment (i.e., patients who
reported with BU deformities), however, a diﬀerent set of
antimycobacterial chemotherapy was used in this study. The
longer stay of patients in the hospital was also ascertained
by the study, especially for patients who reported with BU
deformities, since the mean hospital duration was ﬁfty-two
days.These casesdemonstratethemanagement diﬃcultiesof
BU on the face and suggest that cases of these sorts should be
managed judiciously by professionals in the ﬁeld to enhance
healing.
The study has shown that BUD in central Ghana is
much more widespread than previously thought. In all areas
where BU cases have been identiﬁed, the extent of the
disease is likely to be much greater than currently recognized
through the routine reporting system. According to the
Ghana National BU Program Report of 2009, ten HNR
BU cases were recorded from Agogo Presbyterian Hospital
(AsanteAkimNorthDistrict) andSDAHospitalat Asamang,
Sekyere South (formally Aﬁgya Sekyere) District [12]. This
study conﬁrms that in CentralGhana part of thedistribution
pattern of the disease is in the Ashanti Region; this is very
essential, since it may serve as a guide to other studies and
also serve as a tool to assess the disability impact of BUD,
taking into consideration the HNR of the patients.
TheBUDusuallystartsasanoduleintheskin.Ifthenod-
ule is excised, the extensive ulceration can be prevented [15,
16]. Most of these patients reported very late for treatment,
some even compounded it by using herbal medications,
which were additional source of secondary microorganism
infections. The 2009 Ghana National BU Report indicates
that, 64.2% (N = 508) of the clinical presentations were
ulcers [12], and this had also been conﬁrmed by other
BU studies [10, 11, 15, 21]. As revealed in Table 1 of this
study, most of the clinical presentations recorded were ulcers
aﬀecting almost every part of the HNR of the patients. The
result of the study was in line with the already published
study; majority of the patients who reported to the various
facilities with ulcers were those with deformities that led
to functional disabilities such as blindness which aﬀects
patients in their daily activities. Facial disﬁgurement as a
result of the facial scars due to the surgeries also caused
psychological eﬀects (e.g., low self-esteem, shyness, and
inferiority complex), which could aﬀect the victims in their
education (especially in children), marriage, and work.
BUD on the face in particular posed a series of challenges
to the plastic surgeon. In the ﬁrst place, unlike BUD on
other parts of the body where the surgeon could eventually
excise all the diseased lesions, this is often not possible in
the case of facial BU. The essential organs, especially the
eyes, limit the surgeon who indeed would try to prevent any
iatrogenic injury to the eyes. The leftover diseased tissues
could eventually inﬁltrate the eyes which could lead to their
blindness. In this study, all patients with loss of eyeball
reported to the facility as such, a contributing factor to
the loss of sight is the fact that all patients reported very
late for treatment. Public health education in BUD endemic
communitiesshouldbeintensiﬁed. Thiswill promptpatients
to report early enough for diagnosis and treatment.
Equally important is the management of the disease in
the district hospitals. Most, district and community health
institutions have no “tools” for diagnosis and treatment of
BUD. Equipping and training of health personnel in the
district hospitals is vital, since these facilities are always
the ﬁrst place of visit by most patients. The existing BU
management team, especially in endemic districts should be
provided with all necessary “tools” to facilitate their work.
Establishing surveillance teams in the districts should be a
necessity, for rapid diagnoses of BUD in order to prevent
disabilities. In situations where patients for some reasons
report very late with advanced ulcers,theyshould be referred
immediately to tertiary centers to be managed by specialist.
5.Conclusion
The study demonstrated that visual impairment was the
commonest form of disability in the HNR. Facial scars
caused by BUD also could have a negative impact on
the patients, self-conﬁdent. Thus, management diﬃculties
and disabilities caused by BUD in the HNR of patients
could be avoided by early detection, treatment, and health
education on the disease. The outcome in these patients also
underscores the importance of prompt referral of suspected
cases and training of health professionals at the district levels
in the early diagnosis of BU.
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